---
title: 'Qualitative and quantitative evaluation of computed tomography changes in
  adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective
  observational study'
date: '2023-10-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37808186/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231009180720&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'Introduction: The availability of highly effective triple cystic fibrosis
  transmembrane conductance regulator (CFTR) modulator combination therapy with elexacaftor-tezacaftor-ivacaftor
  (ETI) has improved pulmonary outcomes and quality of life of people with cystic
  fibrosis (pwCF). The aim of this study was to assess computed tomography (CT) changes
  under ETI visually with the Brody score and quantitatively with dedicated software,
  and to correlate CT measures with parameters of ...'
disable_comments: true
---
Introduction: The availability of highly effective triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapy with elexacaftor-tezacaftor-ivacaftor (ETI) has improved pulmonary outcomes and quality of life of people with cystic fibrosis (pwCF). The aim of this study was to assess computed tomography (CT) changes under ETI visually with the Brody score and quantitatively with dedicated software, and to correlate CT measures with parameters of ...